Shire PLC (LON:SHP) has been assigned a consensus recommendation of “Buy” from the twenty ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is GBX 5,256.67 ($70.75).
A number of research firms have recently issued reports on SHP. J P Morgan Chase & Co dropped their price target on Shire from GBX 5,500 ($74.02) to GBX 5,300 ($71.33) and set an “overweight” rating for the company in a research report on Wednesday, September 13th. Goldman Sachs Group reaffirmed a “conviction-buy” rating on shares of Shire in a research report on Tuesday, October 17th. Liberum Capital downgraded shares of Shire to a “hold” rating and lowered their price objective for the company from GBX 4,200 ($56.53) to GBX 4,100 ($55.18) in a research report on Wednesday. Deutsche Bank decreased their target price on shares of Shire from GBX 6,000 ($80.75) to GBX 5,700 ($76.72) and set a “buy” rating for the company in a research report on Tuesday, September 5th. Finally, Morgan Stanley decreased their target price on shares of Shire from GBX 5,800 ($78.06) to GBX 5,700 ($76.72) and set an “overweight” rating for the company in a research report on Thursday, October 12th.
Shares of Shire (LON:SHP) traded down GBX 35.50 ($0.48) during trading on Friday, hitting GBX 3,880.50 ($52.23). 1,662,313 shares of the stock were exchanged, compared to its average volume of 2,580,000. Shire has a 52 week low of GBX 3,435.50 ($46.24) and a 52 week high of GBX 5,067 ($68.20).
In other news, insider Dominic Blakemore acquired 165 shares of the stock in a transaction dated Tuesday, December 19th. The stock was bought at an average price of GBX 3,790 ($51.01) per share, with a total value of £6,253.50 ($8,416.55). Also, insider Anne Minto acquired 190 shares of the stock in a transaction dated Friday, September 29th. The stock was purchased at an average cost of GBX 3,785 ($50.94) per share, with a total value of £7,191.50 ($9,679.00).
COPYRIGHT VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/shire-plc-shp-given-consensus-rating-of-buy-by-analysts.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.